Trastuzumab binds to the HER2 receptor on tumour cells, blocking growth and division;
Stimulates immune response against cancer cells;
Recommended for patients with confirmed HER2-positive breast or gastric tumours;
Used in combination with chemotherapy or as monotherapy under certain conditions.
Treatment of HER2-positive breast cancer in adjuvant and metastatic settings
Treatment of HER2-positive gastric or gastroesophageal junction cancer
The infusion solution is administered intravenously under hospital supervision. Dosage and regimen are individually determined by the physician based on body weight, patient condition, and concomitant therapy. Regular cardiac monitoring is required.
Contraindications:
Hypersensitivity to Trastuzumab or any excipients
Severe heart failure or cardiac rhythm disorders
Acute infections or severe general condition
Pregnancy and lactation without medical supervision
Side effects:
Infusion reactions: fever, chills, headache
Cardiac dysfunction: reduced ejection fraction, heart failure
Nausea, vomiting, diarrhoea
Rarely: allergic reactions, rash, hypersensitivity
